Utilising animal models to evaluate oseltamivir efficacy against influenza A and B viruses with reduced in vitro susceptibility
Rubaiyea Farrukee, Celeste Ming-Kay Tai, Ding Yuan Oh, Danielle E Anderson, Vithiagaran Gunalan, Martin Hibberd, Gary Yuk-Fai Lau, Ian G Barr, Veronika von Messling, Sebastian Maurer-Stroh, Aeron C Hurt
PLOS PATHOGENS | PUBLIC LIBRARY SCIENCE | Published : 2020
The neuraminidase (NA) inhibitor (NAI) oseltamivir (OST) is the most widely used influenza antiviral drug. Several NA amino acid substitutions are reported to reduce viral susceptibility to OST in in vitro assays. However, whether there is a correlation between the level of reduction in susceptibility in vitro and the efficacy of OST against these viruses in vivo is not well understood. In this study, a ferret model was utilised to evaluate OST efficacy against circulating influenza A and B viruses with a range of in vitro generated 50% inhibitory concentrations (IC50) values for OST. OST efficacy against an A(H1N1)pdm09 and an A(H1N1)pdm09 virus with the H275Y substitution in neuraminidase ..View full abstract
Awarded by NHMRC-A.STAR grant
The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health. We further acknowledge the NHMRC-A.STAR grant (APP1055793) for supporting this research work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.